Your browser is no longer supported. Please, upgrade your browser.
CRSP CRISPR Therapeutics AG daily Stock Chart
CRISPR Therapeutics AG
Index- P/E- EPS (ttm)-1.56 Insider Own0.40% Shs Outstand46.63M Perf Week-8.73%
Market Cap2.41B Forward P/E- EPS next Y-3.11 Insider Trans-81.95% Shs Float35.77M Perf Month28.75%
Income-62.10M PEG- EPS next Q-0.67 Inst Own42.70% Short Float3.84% Perf Quarter182.90%
Sales41.00M P/S58.88 EPS this Y18.10% Inst Trans13.97% Short Ratio1.31 Perf Half Y171.05%
Book/sh4.64 P/B11.16 EPS next Y-15.30% ROA-23.20% Target Price37.33 Perf Year152.66%
Cash/sh5.14 P/C10.07 EPS next 5Y- ROE-35.10% 52W Range13.50 - 61.24 Perf YTD120.49%
Dividend- P/FCF- EPS past 5Y- ROI-32.00% 52W High-15.46% Beta-
Dividend %- Quick Ratio17.10 Sales past 5Y- Gross Margin- 52W Low283.48% ATR4.62
Employees127 Current Ratio17.10 Sales Q/Q1279.10% Oper. Margin- RSI (14)59.15 Volatility11.29% 8.56%
OptionableYes Debt/Eq0.00 EPS Q/Q-88.60% Profit Margin- Rel Volume1.06 Prev Close52.60
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.05M Price51.77
Recom2.10 SMA206.49% SMA5029.95% SMA200120.07% Volume1,111,128 Change-1.58%
Mar-08-18Initiated JMP Securities Mkt Outperform $69
Jan-23-18Upgrade SunTrust Hold → Buy
Dec-22-17Initiated Piper Jaffray Overweight
Jul-14-17Initiated SunTrust Hold $16
Mar-28-17Initiated Chardan Capital Markets Buy $23.50
Mar-16-18 06:13AM  3 Reasons CRISPR Stocks Could Keep Soaring Motley Fool
Mar-15-18 05:09PM  Why CRISPR Therapeutics Slipped 10% on Thursday Motley Fool -9.58%
08:10AM  Todays Research Reports on Trending Tickers: CRISPR Therapeutics and Syndax Pharmaceuticals ACCESSWIRE
07:10AM  Here are some biotech song requests for Diana Ross at the 2018 BIO convention American City Business Journals
Mar-14-18 07:40AM  Analysis: Positioning to Benefit within CURO Group, Golar LNG Partners LP, CRISPR Therapeutics AG, Kinross Gold, Enerplus, and ManTech International Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-13-18 07:30AM  Record Revenue Growth & Imminent Nasdaq Listing Could Spell Big Upside for Unknown Orgenesis (ORGS) ACCESSWIRE
Mar-09-18 03:36PM  Here's Why CRISPR Therapeutics AG Gained as Much as 14% Today Motley Fool +5.62%
Mar-08-18 04:15PM  CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Mar-04-18 11:36AM  Here's Why Crispr Therapeutics AG Jumped Again in February Motley Fool
Mar-03-18 07:07AM  3 Stocks That Look Just Like eBay in 1998 Motley Fool
Mar-02-18 09:21PM  Heres Why Gilead Sciences' Jump Into Gene Editing Is Important Motley Fool +7.48%
03:29PM  CRISPR Takes a Leap Forward With Huntington's Disease
Feb-27-18 08:20AM  Todays Research Reports on Stocks to Watch: Ultragenyx Pharmaceutical and CRISPR Therapeutics ACCESSWIRE
Feb-21-18 08:30AM  CRISPR Therapeutics to Participate in Four Upcoming Investor Conferences GlobeNewswire
Feb-15-18 06:02AM  3 Great Acquisition Targets for Gilead Sciences -- and 1 Iffy Candidate Motley Fool
Feb-08-18 04:30PM  CRISPR Therapeutics Announces Transition of Bill Lundberg, MD GlobeNewswire -7.27%
01:35PM  Why Crispr Therapeutics AG Stock Bolted Higher in January Motley Fool
12:55PM  Here's What Pushed Intellia Therapeutics Inc. Up 33.7% in January Motley Fool
Feb-07-18 10:53AM  The Confidence in the Dip Buyers Has Weakened +13.98%
Feb-05-18 07:10PM  Cramer's lightning round: Tableau Software is exactly the... CNBC Videos
Feb-02-18 03:10PM  Can CRISPR And These 3 Small Biotechs Cure 10,000 Diseases? Investor's Business Daily
Jan-31-18 01:29PM  [$$] Bayer Buys More Crispr Stock After Celgene Sells -5.80%
Jan-30-18 12:03PM  Here's Why Editas Medicine Rose as Much as 15.7% Yesterday Motley Fool -6.06%
Jan-28-18 03:28PM  3 Biotech Stocks With Jaw-Dropping Growth Potential Motley Fool
Jan-24-18 08:00AM  Celgene's Been Selling Shares in This Biotech Motley Fool
Jan-23-18 03:50PM  2 Gene Editing Stocks SunTrust Recommends Benzinga +14.90%
12:57PM  Here's What's Driving Crispr Therapeutics AG Higher Today Motley Fool
05:20AM  Chinese scientists used Crispr gene editing on 86 human patients Quartz
Jan-22-18 12:45AM  [$$] China, Unhampered by Rules, Races Ahead in Gene-Editing Trials The Wall Street Journal +13.52%
Jan-16-18 07:34AM  CRISPR Gene-Editing Stocks Going Down the Tubes? Think Again Motley Fool
Jan-09-18 06:09AM  10 Things to Expect From Vertex Pharmaceuticals in 2018 Motley Fool
Jan-08-18 08:46AM  CRISPR Therapeutics (CRSP) Jumps: Stock Rises 12.1% Zacks
08:00AM  Uh-Oh! CRISPR Gene-Editing Stocks May Be Worthless Motley Fool
03:00AM  Stocks Showing Market Leadership: CRISPR Therapeutics Earns 92 RS Rating Investor's Business Daily
Jan-05-18 01:48PM  Why CRISPR Therapeutics AG Stock Is Rising Today Motley Fool +12.13%
12:10PM  Investors Cheer Secondary Offering for Gene-Editing Firm 24/7 Wall St.
Jan-04-18 07:03PM  CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares GlobeNewswire
04:36PM  Here's Why Intellia Therapeutics Inc. Fell 14.7% in December Motley Fool
10:47AM  Here's What Pushed Crispr Therapeutics AG Up 23.6% in December Motley Fool
Jan-03-18 06:15AM  CRISPR Therapeutics Announces Proposed Public Offering of Common Shares GlobeNewswire -6.56%
Dec-27-17 01:24PM  [$$] Celgene: Two Small-Cap Biotech Stocks It's Selling
08:55AM  CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-22-17 12:32PM  CRISPR Therapeutics Stock Wins a Buy Rating: What You Need to Know Motley Fool +8.02%
Dec-21-17 08:00AM  CRISPR Therapeutics Announces Appointment of Dr. Rodger Novak as Chairman of the Board GlobeNewswire
Dec-12-17 08:30AM  Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and -Thalassemia Business Wire
Dec-10-17 09:25PM  Cambridge biotechs among big winners at ASH blood disease conference American City Business Journals
07:45AM  CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Therapy for -Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting GlobeNewswire
Dec-07-17 07:00AM  CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in -thalassemia GlobeNewswire
Dec-05-17 08:00AM  CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Medicine for -Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting GlobeNewswire
07:47AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : December 5, 2017 Capital Cube
Nov-29-17 08:26PM  Bitcoin or CRISPR: Which is the Bigger Disruptor? Zacks
Nov-28-17 08:00AM  CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-22-17 01:15PM  FDA warns against do it yourself gene therapy kits American City Business Journals
Nov-21-17 07:33AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bullish Manner : CRSP-US : November 21, 2017 Capital Cube
Nov-14-17 07:34AM  Disruptor Alert: These 5 Companies Are Changing Healthcare Motley Fool
Nov-13-17 11:20AM  MIT scientists deploy new CRISPR delivery system to edit genes in mice American City Business Journals
08:00AM  CRISPR Therapeutics Announces Appointment of Michael Tomsicek as Chief Financial Officer GlobeNewswire
05:00AM  CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs GlobeNewswire
Nov-10-17 08:00PM  CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC Annual Meeting GlobeNewswire
Nov-08-17 04:05PM  CRISPR Therapeutics Announces Third Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Nov-07-17 03:48PM  Editas CEO to testify at U.S. Senate hearing on gene editing potential, ethics American City Business Journals
11:40AM  Why CRISPR Therapeutics AG Stock Edged Higher in October Motley Fool
08:00AM  CRISPR Therapeutics to Present New Data on Allogeneic CRISPR-based CAR-T Program and Host Investor Reception at the 32nd Annual Society for Immunotherapy of Cancer Meeting GlobeNewswire
07:04AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bullish Manner : CRSP-US : November 7, 2017 Capital Cube
Oct-30-17 12:38PM  CRISPR Therapeutics AG Value Analysis (NASDAQ:CRSP) : October 30, 2017 Capital Cube
Oct-27-17 08:29AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : October 27, 2017 Capital Cube
Oct-13-17 08:30AM  CRISPR Therapeutics Awarded Grant from Friedreichs Ataxia Research Alliance to Collaborate with University of Alabama at Birmingham on Gene-edited Treatments for Friedrichs Ataxia GlobeNewswire
Oct-12-17 08:24AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : October 12, 2017 Capital Cube
Oct-10-17 10:00AM  Why CRISPR Therapeutics AG Stock Lost Ground in September Motley Fool
Oct-04-17 04:01PM  CRISPR Therapeutics to Present at Investor Conferences in October GlobeNewswire
Oct-02-17 07:30AM  CRISPR Therapeutics Announces Promotion of Samarth Kulkarni, Ph.D. to Chief Executive Officer GlobeNewswire
Sep-27-17 08:17AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : September 27, 2017 Capital Cube
Sep-18-17 12:38PM  CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 Capital Cube
Sep-07-17 03:32PM  Breaking Down Barclays' New Bullish Calls On Biotech Benzinga
Aug-31-17 11:29AM  How a CRISPR, gene-editing technology, patent ruling could move stocks Harvest Exchange
Aug-24-17 10:50AM  CRISPR Therapeutics, MGH team up on new cancer treatments American City Business Journals +5.11%
Aug-22-17 07:30AM  CRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer Therapies GlobeNewswire
Aug-13-17 11:01AM  This Technology Could Make You Rich -- and Change the World As We Know It Motley Fool
Aug-10-17 04:35PM  CRISPR Therapeutics Announces Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Aug-01-17 07:00AM  CRISPR Therapeutics Appoints Dr. Tony W. Ho to Head Research & Development GlobeNewswire
Jul-25-17 05:00PM  CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing GlobeNewswire
Jul-17-17 07:06AM  This Is Why Investors Will Need to Learn a New Acronym: CRISPR Motley Fool
Jul-15-17 03:40PM  Never Will I Ever Buy Preclinical Biotech Stocks. No Way! Motley Fool
12:03PM  Why You're Smart to Buy Vertex Pharmaceuticals Stock Motley Fool
Jul-10-17 12:35PM  Why CRISPR Therapeutics AG Jumped 11.7% in June Motley Fool
08:30AM  CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration GlobeNewswire
08:00AM  CRISPR Gene Editing Controversy: Does It Really Cause Unexpected Mutations? Forbes
Jul-09-17 06:02AM  3 Growth Stocks for Forward-Looking Investors Motley Fool
Jul-05-17 04:30PM  CRISPR Therapeutics to Present at the Piper Jaffray GenomeRx Symposium GlobeNewswire
Jun-23-17 08:14AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bullish Manner : CRSP-US : June 23, 2017 Capital Cube
Jun-19-17 07:30AM  CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China GlobeNewswire
Jun-14-17 08:30AM  CRISPR Therapeutics to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-07-17 08:30AM  CRISPR Therapeutics Appoints James R. Kasinger as General Counsel GlobeNewswire
Jun-06-17 03:20PM  Two gene editing firms unveil cancer drug pacts as ASCO comes to a close American City Business Journals
08:30AM  CRISPR Therapeutics and MaSTherCell SA sign service agreement for the development and manufacturing of allogeneic cell therapies GlobeNewswire
Jun-02-17 09:58AM  CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-30-17 04:17PM  Here's Why Editas Medicine Fell as Much as 15.7% Today Motley Fool -5.32%
May-18-17 08:30AM  CRISPR Therapeutics Announces the Presentation of Data on its Lead Program at the Upcoming 22nd European Hematology Association Annual Congress GlobeNewswire
May-16-17 08:00AM  CRISPR Therapeutics and collaborators at the University of Florida awarded Target ALS Grant to develop CRISPR/Cas9-based approaches for ALS GlobeNewswire
May-12-17 04:50PM  CRISPR Therapeutics to Present at Investor Conferences in May GlobeNewswire
CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The CRISPR/Cas9 technology allows for changes to genomic DNA. The company has strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases. It operates in Switzerland, the United States, and the United Kingdom. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CELGENE CORP /DE/10% OwnerNov 21Sale19.2580,0001,540,0004,173,019Dec 07 09:57 AM
Dylan-Hyde TylerChief Legal OfficerJan 16Option Exercise12.5721,000263,97045,094Jan 18 05:38 PM
Dylan-Hyde TylerChief Legal OfficerJan 16Sale28.0366,0001,850,25525,204Jan 18 05:38 PM
BAYER AKTIENGESELLSCHAFT10% OwnerJan 05Buy22.75527,47211,999,9885,632,802Jan 30 02:21 PM
EMSTER KURT VONDirectorJan 05Buy22.7565,9341,499,9991,887,202Jan 11 09:00 PM
EMSTER KURT VONDirectorJan 05Sale26.9692,3372,489,4061,821,268Jan 09 04:39 PM
Dylan-Hyde TylerChief Legal OfficerJan 02Option Exercise12.578,000100,56078,204Jan 04 07:14 PM
Dylan-Hyde TylerChief Legal OfficerJan 02Sale21.6438,000822,50070,204Jan 04 07:14 PM
EMSTER KURT VONDirectorJan 02Sale26.7637,7541,010,1231,913,605Jan 04 05:29 PM
Dylan-Hyde TylerChief Legal OfficerDec 29Option Exercise13.3315,300203,909124,274Jan 02 04:18 PM
Dylan-Hyde TylerChief Legal OfficerDec 29Sale22.7430,300689,055100,204Jan 02 04:18 PM
Dylan-Hyde TylerChief Legal OfficerDec 28Option Exercise14.4370010,101115,904Jan 02 04:18 PM
Dylan-Hyde TylerChief Legal OfficerDec 28Sale21.7570015,225115,204Jan 02 04:18 PM
Bolzon Bradley J PhDDirectorDec 22Sale20.3026,016528,23727,724Dec 27 04:17 PM
Dylan-Hyde TylerChief Legal OfficerDec 22Sale20.5515,000308,250115,204Dec 27 04:17 PM
Woiwode ThomasDirectorDec 22Sale20.293,05962,0704,959Dec 27 04:14 PM
Kulkarni SamarthChief Executive OfficerDec 21Option Exercise1.8115,00027,150148,560Dec 26 05:11 PM
Dylan-Hyde TylerChief Legal OfficerDec 15Sale18.9015,000283,496130,204Dec 19 04:10 PM
CELGENE CORP /DE/10% OwnerDec 04Sale19.4730,485593,5433,722,534Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerDec 01Sale19.1087,9911,680,6283,753,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 30Sale19.0412,666241,1613,841,010Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 29Sale19.254,26382,0633,853,676Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 28Sale19.225,08097,6383,857,939Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 27Sale19.7527,990552,8033,863,019Dec 07 09:57 AM
Bolzon Bradley J PhDDirectorNov 27Sale20.242004,04853,740Nov 28 04:10 PM
Woiwode ThomasDirectorNov 27Sale20.242004,0488,018Nov 28 04:11 PM
Woiwode ThomasDirectorNov 24Sale20.211,70034,3588,218Nov 28 04:11 PM
Bolzon Bradley J PhDDirectorNov 24Sale20.211,50730,45053,940Nov 28 04:10 PM
CELGENE CORP /DE/10% OwnerNov 24Sale20.0026,010520,2003,891,009Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 22Sale19.76256,0005,058,5603,917,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 20Sale19.02158,7183,018,8164,253,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 17Sale18.4451,282945,6404,411,737Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 16Sale18.39105,0001,930,9504,463,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 15Sale17.6715,000265,0504,568,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 14Sale17.1914,907256,2514,583,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 13Sale17.7665,0931,156,0524,597,926Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 10Sale17.2810,000172,8004,663,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 09Sale17.0820,000341,6004,673,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 08Sale18.0616,875304,7634,693,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 07Sale18.5423,000426,4204,709,894Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 06Sale18.8979,3271,498,4874,732,894Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 03Sale19.1022,759434,6974,812,221Dec 07 09:57 AM
Novak RodgerChief Executive OfficerSep 05Option Exercise1.813,8536,9741,151,860Sep 05 06:33 PM
Novak RodgerChief Executive OfficerSep 05Sale20.333,85378,3201,148,007Sep 05 06:33 PM
Novak RodgerChief Executive OfficerAug 31Sale20.8714,617305,0731,148,007Sep 05 06:33 PM